Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296289 | 1.00 | MARK3 (0.40) | MARK3NTRK1IGF1RCYP3A4KCNH2 | |
| SCHEMBL2291630 | 0.84 | MARK3 (0.47) | MARK3NTRK1IGF1RCYP3A4CAMKK1 | |
| SCHEMBL12418674 | 0.84 | MARK3 (0.47) | MARK3NTRK1IGF1RCAMKK1CAMKK2 | |
| SCHEMBL2291253 | 0.82 | MARK3 (0.41) | MARK3IGF1RCYP3A4KCNH2CAMKK1 | |
| SCHEMBL2289543 | 0.79 | KDM4E (0.53) | KDM4ENPC1ALDH1A1HTTRAB9A | |
| SCHEMBL2292190 | 0.79 | IRAK4 (0.41) | MARK3CAMKK1CAMKK2CDK2 | |
| SCHEMBL15108345 | 0.78 | NPC1 (0.44) | KDM4ENPC1ALDH1A1HTTRAB9A | |
| SCHEMBL2293160 | 0.78 | ALDH1A1 (0.46) | KDM4ENPC1ALDH1A1HTTRAB9A | |
| SCHEMBL2292887 | 0.78 | EPHB3 (0.37) | MARK3IGF1RCYP3A4KCNH2CAMKK1 | |
| SCHEMBL2288445 | 0.78 | DGAT2 (0.39) | MARK3IGF1RCYP3A4KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | claimed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | claimed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518911-B2 | Pyrazolo[1,5-a]pyridines as MARK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2320737-B1 | PYRAZOLO-[1,5-A]-PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MARK3, MARK4, MARK1 | MARK3 1/4885NTRK1 637/4885IGF1R 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.